Tomo Ando, MD

The comparison between UGT1A1 single heterozygous and wild-type regarding the clinical outcomes of fixed-dose irinotecan monotherapy for advanced gastric cancer: a multicenter retrospective study

Introduction Irinotecan is a key drug for advanced gastric cancer (AGC). We previously reported that patients with UGT1A1 single heterozygous (SH) had a significantly high frequency of s...

T. Miyagishima ;

A. Tanimoto ;

S. Yuki ;

T. Honda ;

Y. Komatsu ;

Y. Kobayashi ;

T. Sasaki ;

Y. Kawamoto ;

A. Ishiguro ;

K. Hatanaka ;

M. Dazai ;

H. Nakatsumi ;

Tomo Ando , MD;

H. Yoshita ;

S. Nakano ;

K. Sawada ;

T. Muranaka ;

K. Harada ;

07/01/2019

Original Contribution

Spontaneous Echocardiographic Contrast in the Left Atrium During Transcatheter Aortic Valve Replacement is Associated With Worse Outcomes

03/29/2016

David Paul Slovut , MD, PhD;

Anthony A. Holmes , MD;

Cynthia C. Taub , MD;

Tomo Ando , MD;

We assessed the impact of spontaneous echocardiographic contrast on outcomes after TAVR by retrospectively reviewing the medical records of 93 consecutive patients who underwent TAVR at a single center.

We assessed the impact of...

03/29/2016

Journal of Invasive Cardiology

A phase II study of weekly paclitaxel in patients with advanced or recurrent esophageal cancer who had previously received docetaxel-containing chemotherapy

Background Both docetaxel and paclitaxel are a class of microtubule-stabilizing anticancer agents. Partial cross-resistance between docetaxel and paclitaxel was indicate...

K. Yoshimura ;

Tomo Ando , MD;

K. Nakashima ;

H. Yoshita ;

M. Sakumura ;

M. Nomura ;

M. Muto ;

Y. Horie ;

H. Takeda ;

T. Yoshii ;

Y. Tahara ;

C. Katada ;